PGP and epilepsy: Interest of pharmaceutical industry in developing selective Pgp inhibitors for add-on epilepsy therapy has declined after the failure of such Pgp inhibitors in several large cancer trials, which was mainly due to the unexpected toxicity of add-on treatment with Pgp inhibitors as a result of increased penetration and accumulation of cytotoxic chemotherapeutics in normal tissues [74].